UY28202A1 - Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares. - Google Patents

Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares.

Info

Publication number
UY28202A1
UY28202A1 UY28202A UY28202A UY28202A1 UY 28202 A1 UY28202 A1 UY 28202A1 UY 28202 A UY28202 A UY 28202A UY 28202 A UY28202 A UY 28202A UY 28202 A1 UY28202 A1 UY 28202A1
Authority
UY
Uruguay
Prior art keywords
treatment
transits
steroids
people
suffer
Prior art date
Application number
UY28202A
Other languages
English (en)
Spanish (es)
Inventor
David P Bingaman
Abbot F Clark
Stella M Robertson
Rajni Jani
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of UY28202A1 publication Critical patent/UY28202A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY28202A 2003-02-20 2004-02-19 Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares. UY28202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44894303P 2003-02-20 2003-02-20

Publications (1)

Publication Number Publication Date
UY28202A1 true UY28202A1 (es) 2004-08-31

Family

ID=32908674

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28202A UY28202A1 (es) 2003-02-20 2004-02-19 Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares.

Country Status (16)

Country Link
US (2) US20040171598A1 (enExample)
EP (1) EP1670480A4 (enExample)
JP (1) JP2006518382A (enExample)
KR (1) KR20050102652A (enExample)
CN (1) CN1750828A (enExample)
AR (1) AR043251A1 (enExample)
AU (1) AU2004212895A1 (enExample)
BR (1) BRPI0407693A (enExample)
CA (1) CA2516782A1 (enExample)
MX (1) MXPA05008561A (enExample)
PL (1) PL378210A1 (enExample)
RU (1) RU2005129276A (enExample)
TW (1) TW200511996A (enExample)
UY (1) UY28202A1 (enExample)
WO (1) WO2004073607A2 (enExample)
ZA (1) ZA200505989B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004277864A1 (en) * 2003-09-23 2005-04-14 Alcon, Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050245497A1 (en) * 2004-04-08 2005-11-03 Penfold Philip L Treatment of ophthalmic conditions
CA2602577C (en) * 2005-10-18 2015-03-31 Allergan, Inc. Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
US20080076742A1 (en) * 2005-10-31 2008-03-27 Wisconsin Alumni Research Foundation Methods and compositions for treating diseases associated with neovascualrization
ITRM20050547A1 (it) * 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
DK2262506T3 (da) 2008-03-11 2014-06-10 Alcon Res Ltd Meget flokkulerede triamcinolonacetonid-suspensioner med lav viskositet til intravitreal injektion
TW201105363A (en) 2009-07-14 2011-02-16 Univ Yamagata Eye drop for macular edema treatment
ES2641144T3 (es) * 2010-05-10 2017-11-07 Inserm (Institut National De La Santé Et De La Recherche Medicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
KR101106074B1 (ko) * 2011-05-27 2012-01-18 김선미 교통 시설물 설치용 부착대 및 지주장치
WO2015180736A1 (en) 2014-05-30 2015-12-03 Aarhus Universitet Cafestol for treating diabetes
BR112017019025A2 (pt) 2015-03-06 2018-07-31 Envisia Therapeutics Inc aplicadores de implante e métodos para administrar implantes.
CN115337254A (zh) 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
JP2019534063A (ja) 2016-09-02 2019-11-28 エンビシャ セラピューティクス インコーポレイテッド インプラントアプリケータ
EP3691654A4 (en) * 2017-09-25 2021-11-24 Surface Pharmaceuticals, Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6172054B1 (en) * 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
PT1221918E (pt) * 1999-10-21 2005-06-30 Alcon Inc Administracao de drogas sub-tenon
KR100732262B1 (ko) * 1999-10-21 2007-06-25 알콘, 인코퍼레이티드 약물 전달 장치
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
US20030023228A1 (en) * 2001-07-20 2003-01-30 Parkinson Thomas M. Ocular iontophoretic device and method for using the same

Also Published As

Publication number Publication date
CA2516782A1 (en) 2004-09-02
EP1670480A4 (en) 2007-10-10
US20060154910A1 (en) 2006-07-13
TW200511996A (en) 2005-04-01
CN1750828A (zh) 2006-03-22
PL378210A1 (pl) 2006-03-20
WO2004073607A3 (en) 2004-11-25
ZA200505989B (en) 2006-12-27
AR043251A1 (es) 2005-07-20
KR20050102652A (ko) 2005-10-26
EP1670480A2 (en) 2006-06-21
AU2004212895A1 (en) 2004-09-02
MXPA05008561A (es) 2005-11-04
JP2006518382A (ja) 2006-08-10
US20040171598A1 (en) 2004-09-02
WO2004073607A2 (en) 2004-09-02
RU2005129276A (ru) 2006-01-27
BRPI0407693A (pt) 2006-03-01

Similar Documents

Publication Publication Date Title
UY28202A1 (es) Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares.
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
MX2021004191A (es) Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
NO20070330L (no) Retinalderivater og fremgangsmater for anvendelse derav til behandling av synsforstyrrelser
MXPA06014470A (es) Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas.
ATE429914T1 (de) Verwendung von makroliden zur wiederherstellung der kornealempfindungen
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
CL2008001303A1 (es) Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer.
AR075909A1 (es) Un articulo absorbente.
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
AR059928A1 (es) Metodos y dispositivos oftalmicos usados en el tratamiento de alergias oculares
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
AR048135A1 (es) Uso de gen de amiloide a serico en el diagnostico y tratamiento del glaucoma y en la identificacion de agentes anti-glaucoma.
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
CY1106409T1 (el) Παραγωγα κινολινης
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
CY1111384T1 (el) Διαμορφωση των επιπεδων εκφρασης toy trpv
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140610